Ramesh Ramalingam

2018-10-18 07:16
(968 d 07:16 ago)

Posting: # 19463
Views: 1,472

 Theophylline ER 450 mg study design [Design Issues]

Dear Members,

Based on literature reference, Theophylline is a narrow therapeutic index drug. As per USFDA recommendation if the drugs falls under narrow therapeutic index, the BE study should be a fully replicated crossover design in order to:
• Scale bioequivalence limits to the variability of the reference product; and
• Compare test and reference products within-subject variability.

But respective molecule OGD (which was issued on 2010) Draft guidelines recommending two-way cross-over study design.

Could you please suggest the study design whether it should be two-period, two-way crossover design or four period, fully replicated design.

 Admin contact
21,518 posts in 4,498 threads, 1,523 registered users;
online 12 (0 registered, 12 guests [including 9 identified bots]).
Forum time: Saturday 14:33 CEST (Europe/Vienna)

If I find 10,000 ways something won’t work, I haven’t failed.
I am not discouraged, because every wrong attempt discarded
is another step forward.    Thomas Alva Edison

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz